UK drug discovery company, C4X Discovery Holdings PLC, has launched its precision medicine platform, PatientSeek, which is designed to identify patients that are most likely to respond positively to a medication based on their genetic profile. 

The platform’s release comes after its initial validation for patient stratification, using data obtained from an unsuccessful Phase III clinical trial centered around Parkinson’s disease. The retrospective analysis identified a subgroup of patients that responded to the treatment, despite the trial’s overall failure.

The company also plans to deploy PatientSeek to investigate immunoinflammatory diseases with a focus on analyzing data sets related to rheumatoid arthritis and inflammatory bowel disease.

C4X Discovery uses mathematical algorithms and genetic data to identify potential drug targets and develop new therapies for a range of diseases. Its approach allows the discovery of targets that cause underlying diseases, rather than just those associated with symptoms, and provides a better starting point for drug discovery, as well as patient stratification and biomarker identification. C4X Discovery is currently working on developing therapies for Parkinson’s disease, inflammatory bowel disease, rheumatoid arthritis, and hematological cancers.